What will be the impact on PRAX news tomorrow stock ?

The impact on PRAX news tomorrow's stock will likely be positive, considering the recent developments surrounding Praxis Precision Medicines, Inc. Here's an analysis of the factors that could influence the stock's performance:

1. **Breakthrough Therapy Designation**: The FDA's breakthrough therapy designation for relutrigine in treating SCN2A and SCN8A developmental and epileptic encephalopathies is a significant milestone. This designation can lead to accelerated development and approval processes, potentially increasing investor confidence in the company's future prospects.
2. **Upcoming Clinical Study Results**: Praxis has several clinical trials underway, including the RADIANT study for vormatrigine and the EMERALD study for relutrigine. The anticipation of topline results, especially for vormatrigine, could lead to increased investor optimism. The quiet period preceding the RADIANT study's topline results has likely created a sense of anticipation that could translate into positive momentum when the results are announced.
3. **Analyst Ratings and Price Targets**: Analysts have maintained bullish ratings for Praxis Precision Medicines, with a price target of $270 from Piper Sandler, indicating a potential upside from the current trading price. This positive sentiment from analysts can bolster investor confidence and drive stock prices higher.

In conclusion, the combination of breakthrough therapy designation, upcoming clinical study results, and analyst ratings suggest that PRAX news tomorrow could be positive, with a potential for stock price appreciation. However, it's important to note that market dynamics can change rapidly, and specific results of the clinical trials and their impact on the company's future prospects will be crucial factors.